CLBX — Cellbxhealth Share News
0.000.00%
Last trade - 00:00- £9.40m
- £7.84m
- £1.35m
Brief: Cellbxhealth Enters Master Services Agreement With Swiss Biotech
Master Services Agreement with Swiss biotech co
Q3 Trading Update and FY 2026 Outlook
Brief: Cellbxhealth Signs New Statement Of Work With US-Based Pharma Company
New Statement of Work with US-Based Pharma Company
Parsortix CTCs used for Brain Cancer detection
Parsortix CTCs used for ADC target assessment
Issue of Share Options
Brief: CelLBxHealth Says Board Expects To Be EBITDA Positive In 2028
Q2 and First Half Year Results ended 30 June 2026
Brief: Cellbxhealth Expects FY 2026 Revenues Of At Least £2.1 Million
AGM Statement
Brief: CelLBxHealth Says Peter Collins Steps Down As CEO Of Co
Directorate change
Brief: Cellbxhealth Expects FY 2026 Revenue Of At Least £2.1 Mln
Notice of Results
Brief: CelLBxHealth Enters Master Services Agreement With AstraZeneca
MSA with Global Pharmaceutical Company
Collaboration with AdventHealth for two studies